Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Return on Equity (2017 - 2025)

Adma Biologics (ADMA) has disclosed Return on Equity for 13 consecutive years, with 0.35% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity fell 33.0% year-over-year to 0.35%, compared with a TTM value of 0.35% through Dec 2025, down 33.0%, and an annual FY2025 reading of 0.38%, down 43.0% over the prior year.
  • Return on Equity was 0.35% for Q4 2025 at Adma Biologics, down from 0.5% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.68% in Q4 2024 and bottomed at 0.75% in Q1 2021.
  • Average Return on Equity over 5 years is 0.1%, with a median of 0.27% recorded in 2023.
  • The sharpest move saw Return on Equity surged 64bps in 2024, then plummeted -33bps in 2025.
  • Year by year, Return on Equity stood at 0.59% in 2021, then rose by 21bps to 0.46% in 2022, then skyrocketed by 68bps to 0.15% in 2023, then soared by 553bps to 0.68% in 2024, then tumbled by -49bps to 0.35% in 2025.
  • Business Quant data shows Return on Equity for ADMA at 0.35% in Q4 2025, 0.5% in Q3 2025, and 0.54% in Q2 2025.